ElizabethIBuchbinderMD

Oncology • Boston, MA

Hematologic Oncology, Melanoma

Instructor in Medicine, Dana Farber Cancer Institute

Join to view full profile

Dr. Buchbinder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Buchbinder's full profile

Already have an account?

Office
Dana Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02115
Phone+1 617-632-5055

Summary

Dr. Elizabeth Buchbinder is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. She received her medical degree from Tufts University School of Medicine and has been in practice 13 years. She specializes in hematologic oncology and melanoma and is experienced in melanoma and cutaneous malignancies.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
Tufts University School of MedicineClass of 2004

Certifications & Licensure

ME State Medical License 2022 - 2026
OH State Medical License 2024 - 2026
RI State Medical License 2022 - 2026
VT State Medical License 2022 - 2026
MA State Medical License 2006 - 2025
NH State Medical License 2023 - 2025
CT State Medical License 2022 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Utility of Novel BRAF Test for Melanoma Start of enrollment: 2013 May 01
Active, not recruiting
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma Start of enrollment: 2017 Jun 06
Active, not recruiting
Phase 1, Phase 2
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Start of enrollment: 2018 Mar 26
Active, not recruiting
Phase 2
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma Start of enrollment: 2018 Jun 22
Active, not recruiting
Phase 1, Phase 2
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Start of enrollment: 2018 Sep 21
Completed
Phase 3
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Start of enrollment: 2019 Sep 06
Withdrawn
Phase 2
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis Start of enrollment: 2020 Aug 31
Recruiting
Phase 2
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma Start of enrollment: 2020 Aug 06
Recruiting
Phase 2
Sargramostim (GM-CSF) + PD-1 Start of enrollment: 2021 Apr 16
Withdrawn
Phase 2
Roles: Contact, Principal Investigator
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma Start of enrollment: 2020 Jun 12
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.
Giuseppe Tarantino, Cora A Ricker, Annette Wang, William Ge, Tyler J Aprati
Science Advances. 2024-11-29
Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.
Karam Khaddour, Rizwan Haq, Elizabeth I Buchbinder, David Liu, Michael P Manos
The Oncologist. 2024-11-06
Stratified analysis identifies HIF-2as a therapeutic target for highly immune-infiltrated melanomas.
Amy Y Huang, Kelly P Burke, Ryan Porter, Lynn Meiger, Peter Fatouros
Biorxiv. 2024-10-30

Journal Articles

Prognostic Gene Expression Profiling in Cutaneous Melanoma
Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology

Lectures

Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Authored Content

Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020

Press Mentions

Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024September 11th, 2024
Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaFebruary 24th, 2023
Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-Targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid TumorsJanuary 17th, 2023
Join now to see all